On November 7, 2024 AbCellera (Nasdaq: ABCL) reported new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas (Press release, AbCellera, NOV 7, 2024, View Source [SID1234647990]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AbCellera’s presentation, which is available for viewing here, describes:

Strategies to address key challenges in TCE development:

CD3-binding antibodies to widen the therapeutic window by generating TCEs with potent tumor-cell killing and optimal cytokine release
Molecules to enhance efficacy for solid tumor indications by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB
Application of the platform to two of AbCellera’s TCE programs:

Preclinical characterization of TCEs against solid tumor targets B7-H4 and PSMA show tumor-cell killing and cytokine release profiles that are differentiated from clinical benchmarks